XML 17 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2021
Dec. 31, 2020
Jun. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:              
Net loss attributable to Myriad Genetics, Inc. stockholders $ (4.7) $ (39.5) $ (55.4) $ (115.2) $ (44.2)   $ (170.6)
Adjustments to reconcile net loss to net cash provided by operating activities:              
Depreciation and amortization 16.9   17.7   35.3   35.6
Non-cash interest expense         0.8   0.3
Non-cash lease expense         6.8   6.3
Stock-based compensation expense         17.9   9.4
Deferred income taxes         (11.5)   (49.0)
Unrecognized tax benefits         0.4   1.0
Change in fair value of contingent consideration         1.3   (3.4)
Loss on inventory 6.6       6.6   0.0
Impairment of goodwill and long-lived assets         1.8   98.4
Gain on deconsolidation of subsidiary         0.0   (1.0)
Gain on sale of assets         (32.4)   0.0
Changes in assets and liabilities:              
Prepaid expenses         (4.7)   2.4
Trade accounts receivable         (12.3)   50.3
Other receivables         0.3   0.9
Inventory         (0.8)   (0.9)
Prepaid taxes         89.8   24.7
Other assets         (2.7)   0.0
Accounts payable         8.1   0.6
Accrued liabilities         16.1   12.7
Deferred revenue         (9.2)   29.1
Net cash provided by operating activities         67.4   46.8
CASH FLOWS FROM INVESTING ACTIVITIES:              
Capital expenditures         (11.6)   (5.3)
Proceeds from sale of subsidiary         0.0   21.3
Proceeds from sale of assets         32.5   0.0
Purchases of marketable investment securities         (36.6)   (15.8)
Proceeds from maturities and sales of marketable investment securities         25.0   33.4
Net cash provided by investing activities         9.3   33.6
CASH FLOWS FROM FINANCING ACTIVITIES:              
Proceeds from common stock issued under stock-based compensation plans         50.1   2.2
Payment of tax withheld for common stock issued under stock-based compensation plans         (0.6)   (0.1)
Payment of contingent consideration recognized at acquisition         (3.3)   0.0
Fees associated with refinancing of revolving credit facility         (1.2)   (1.0)
Repayment of revolving credit facility         (120.0)   0.0
Net cash provided by (used in) financing activities         (75.0)   1.1
Effect of foreign exchange rates on cash and cash equivalents         (0.3)   (0.5)
Change in cash and cash equivalents classified as held for sale         0.0   1.5
Net increase in cash and cash equivalents         1.4   82.5
Cash and cash equivalents at beginning of the period   $ 117.0   $ 81.2 117.0 $ 163.7 81.2
Cash and cash equivalents at end of the period $ 118.4   $ 163.7   $ 118.4 $ 117.0 $ 163.7